title: Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors.
abstract: In cell cultures, the key residues associated with HIV-1 resistance to cyclic urea-based HIV-1 protease (PR) inhibitors are Val82 and Ile84 of HIV-1 PR. To gain an understanding of how these two residues modulate inhibitor binding, we have measured the Ki values of three recombinant mutant proteases, I84V, V82F, and V82F/I84V, for DMP323 and DMP450, and determined the three-dimensional structures of their complexes to 2.1-1.9 A resolution with R factors of 18.7-19.6%. The Ki values of these mutants increased by 25-, 0.5-, and 1000-fold compared to the wild-type values of 0.8 and 0.4 nM for DMP323 and DMP450, respectively. The wild-type and mutant complexes overall are very similar (rms deviations of 0.2-0.3 A) except for differences in the patterns of their van der Waals (vdw) interactions, which appear to modulate the Ki values of the mutants. The loss of the CD1 atom of Ile84, in the I84V mutant complexes, creates a hole in the S1 subsite, reducing the number of vdw contacts and increasing the Ki values. The V82F mutant binds DMP323 more tightly than wild type because the side chain of Phe82 forms additional vdw and edge-to-face interactions with the P1 group of DMP323. The Ki values of the single mutants are not additive because the side chain of Phe82 rotates out of the S1 subsite in the double mutant (the chi 1 angles of Phe82 and -182 in the V82F and V82F/I84V mutants differ by 90 and 185 degrees, respectively), further reducing the vdw interactions. Finally, compensatory shifts in the I84V and V82F/ I84V complexes pick up a small number of new contacts, but too few to offset the initial loss of interactions caused by the mutations. Therefore, our data suggest that variants persist in the presence of DMP323 and DMP450 because of a decrease in vdw interactions between the mutant proteases and inhibitors.
authors.affiliation: Department of Chemical and Physical Sciences, DuPont Merck Pharmaceutical Company, Wilmington, Delaware 19880-0024, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Ala
authors.forename: E E
authors.initials: EE
authors.lastname: Huston
authors.forename: R M
authors.initials: RM
authors.lastname: Klabe
authors.forename: D D
authors.initials: DD
authors.lastname: McCabe
authors.forename: J L
authors.initials: JL
authors.lastname: Duke
authors.forename: C J
authors.initials: CJ
authors.lastname: Rizzo
authors.forename: B D
authors.initials: BD
authors.lastname: Korant
authors.forename: R J
authors.initials: RJ
authors.lastname: DeLoskey
authors.forename: P Y
authors.initials: PY
authors.lastname: Lam
authors.forename: C N
authors.initials: CN
authors.lastname: Hodge
authors.forename: C H
authors.initials: CH
authors.lastname: Chang
mesh_terms: D001381:Azepines / Q000737:chemistry / Q000494:pharmacology*; D001665:Binding Sites / Q000235:genetics; D018360:Crystallography, X-Ray; D004352:Drug Resistance, Microbial; D016333:HIV Protease / Q000737:chemistry* / Q000187:drug effects / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D007700:Kinetics; D008969:Molecular Sequence Data; D016254:Mutagenesis, Insertional; D011487:Protein Conformation; D013329:Structure-Activity Relationship; D014508:Urea / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology
chemical_list: D001381:Azepines; D017320:HIV Protease Inhibitors; D014508:Urea; D016333:HIV Protease; C085816:DMP 323; C099851:DMP 450